Eli Health

Eli Health, based in Montreal, Canada, focuses on innovative health solutions that enhance women's hormonal health and wellness through advanced hormone testing and personalized management. Eli Health, founded in 2019, is dedicated to improving women's health, particularly in hormone management. The company has not undergone any significant pivots or changes in strategy. Its founders, Marina Rivas and Thomas Cortina, have sought to create a meaningful impact in women's health.

The firm operates out of its headquarters in Montreal, Canada. In its latest funding round on June 10, 2025, Eli Health raised CAD 17 million in Series A funding led by BDC Capital, with participation from several investors including Accelia Capital and TELUS Ventures. This round constituted the total amount raised, totaling CAD 17 million. Eli Health specializes in innovative health solutions focusing on women's health and hormone management.

They offer advanced hormone testing kits that empower women to understand and manage their hormonal health effectively. These kits utilize proprietary technology for accurate hormone level assessments, addressing imbalances and promoting informed health decisions. The products cater to women at various life stages, including pre-menopause, menopause, and post-menopause, targeting individual consumers, healthcare providers, and wellness practitioners across North America and Europe. Eli Health generates revenue through a direct-to-consumer model with a subscription-based service for hormone testing kits.

Customers can subscribe to receive hormone assessment kits regularly or choose one-time purchases. The flexible pricing structure caters to individual health needs and encourages ongoing health monitoring. Additionally, Eli Health collaborates with healthcare providers and wellness professionals to facilitate the integration of its products into therapeutic practices, enhancing market reach and fostering long-term client relationships. Eli Health plans to leverage its recent CAD 17 million Series A funding, received in June 2025, to expand manufacturing capabilities and advance the development of additional biomarkers.

The company aims to deepen its role in personalized health and expedite access to its technology. Eli Health is also targeting expansion into new markets, although specific regions have not been disclosed. The funding will support these strategic initiatives to enhance product offerings and geographic presence.